Prothena Corp (PRTA) Ph1 Results Show Slowing of Neuropathy Progression, Oppenheimer Raises PT to $25
Tweet Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and raised the price target to $25.00 (from $20.00) on Prothena Corp ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
